PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14517454-3 1998 NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription. Doxorubicin 98-109 nuclear factor kappa B subunit 1 Homo sapiens 0-9 9616159-1 1998 Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin have been shown to activate a nuclear factor kappaB (NFkappaB)-dependent program that may rescue cells from apoptosis induction. Doxorubicin 99-110 nuclear factor kappa B subunit 1 Homo sapiens 141-162 9616159-1 1998 Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin have been shown to activate a nuclear factor kappaB (NFkappaB)-dependent program that may rescue cells from apoptosis induction. Doxorubicin 99-110 nuclear factor kappa B subunit 1 Homo sapiens 164-172 9616159-6 1998 Moreover, both in cell lines and in primary leukemia cells that are resistant towards induction of apoptosis by DILs and doxorubicin, antagonization of NFkappaB activity partially restored apoptosis sensitivity. Doxorubicin 121-132 nuclear factor kappa B subunit 1 Homo sapiens 152-160 14517454-3 1998 NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription. Doxorubicin 98-109 nuclear factor kappa B subunit 1 Homo sapiens 257-266 14517454-3 1998 NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription. Doxorubicin 98-109 nuclear factor kappa B subunit 1 Homo sapiens 257-266 14517454-3 1998 NF-kappaB was specifically activated by the genotoxic anticancer therapeutic agents etoposide and doxorubicin, but not by bleomycin, mitomycin C and cisplatin, in human vascular endothelial cells in three independent assay systems: nuclear translocation of NF-kappaB, binding of NF-kappaB to its consensus sequence, and NF-kappaB -dependent transcription. Doxorubicin 98-109 nuclear factor kappa B subunit 1 Homo sapiens 257-266 14517454-5 1998 Co-administration of NF-kappaB antisense oligonucleotides inhibited the angiogenesis by doxorubicin and etoposide. Doxorubicin 88-99 nuclear factor kappa B subunit 1 Homo sapiens 21-30 34589399-0 2021 Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-kappaB and RAS/RAF/MEK/ERK signaling pathway. Doxorubicin 36-47 nuclear factor kappa B subunit 1 Homo sapiens 168-177 9169462-4 1997 Like paclitaxel, vinblastine, vincristine, daunomycin, and doxorubicin each caused activation of NF-kappaB. Doxorubicin 59-70 nuclear factor kappa B subunit 1 Homo sapiens 97-106 33775688-4 2021 Since NF-kappaB activity is considered to be relatively high in particular when it comes to breast cancer, in the present work, we proposed that the inhibition of NF-kappaB activity can augment and enhance the sensitivity of breast cancer cells to chemotherapy such as doxorubicin (DOX) by virtue of MDR modulation. Doxorubicin 269-280 nuclear factor kappa B subunit 1 Homo sapiens 6-15 33775688-4 2021 Since NF-kappaB activity is considered to be relatively high in particular when it comes to breast cancer, in the present work, we proposed that the inhibition of NF-kappaB activity can augment and enhance the sensitivity of breast cancer cells to chemotherapy such as doxorubicin (DOX) by virtue of MDR modulation. Doxorubicin 269-280 nuclear factor kappa B subunit 1 Homo sapiens 163-172 33775688-4 2021 Since NF-kappaB activity is considered to be relatively high in particular when it comes to breast cancer, in the present work, we proposed that the inhibition of NF-kappaB activity can augment and enhance the sensitivity of breast cancer cells to chemotherapy such as doxorubicin (DOX) by virtue of MDR modulation. Doxorubicin 282-285 nuclear factor kappa B subunit 1 Homo sapiens 6-15 33775688-4 2021 Since NF-kappaB activity is considered to be relatively high in particular when it comes to breast cancer, in the present work, we proposed that the inhibition of NF-kappaB activity can augment and enhance the sensitivity of breast cancer cells to chemotherapy such as doxorubicin (DOX) by virtue of MDR modulation. Doxorubicin 282-285 nuclear factor kappa B subunit 1 Homo sapiens 163-172 33775688-5 2021 Our results demonstrated that the DOX-resistant MCF-7 and MDA-MB-231 clones exhibit higher NF-kappaB (p65) function, which is linked to the upregulated expression of ABCB1 and ABCC1 transporter proteins. Doxorubicin 34-37 nuclear factor kappa B subunit 1 Homo sapiens 91-100 33775688-8 2021 The DOX/NF-kappaB inhibitor combinations hampered NF-kappaB (p65) activation and downregulated MDR efflux transporters" level. Doxorubicin 4-7 nuclear factor kappa B subunit 1 Homo sapiens 8-17 33775688-8 2021 The DOX/NF-kappaB inhibitor combinations hampered NF-kappaB (p65) activation and downregulated MDR efflux transporters" level. Doxorubicin 4-7 nuclear factor kappa B subunit 1 Homo sapiens 50-59 34343539-10 2021 Of note, doxorubicin induced the expression of myocardial nuclear NF-kappaB-p65 and caspase-3 which were markedly inhibited by trifluoperazine, suggesting that cardioprotection conferred by trifluoperazine involved, at least in part, suppression of NF-kappaB and apoptosis. Doxorubicin 9-20 nuclear factor kappa B subunit 1 Homo sapiens 249-258 33775688-9 2021 Breast cancer cell migration was sharply suppressed in cells co-treated with DOX/NF-kappaB inhibitors. Doxorubicin 77-80 nuclear factor kappa B subunit 1 Homo sapiens 81-90 33773562-17 2021 Phospho-Akt, NFkappaB consequentially decreased doxorubicin accumulation by enhancing the expressions of ABCG2 and Pgp1 respectively. Doxorubicin 48-59 nuclear factor kappa B subunit 1 Homo sapiens 13-21 34488792-5 2021 RESULTS: Nano-DOX were first shown to stimulate the tumor cells and the TAMs to release the cytokine HMGB1 which, regardless of its source, acted through the RAGE/NF-kappaB pathway to induce PD-L1 in the tumor cells and PD-L1/PD-1 in the TAMs. Doxorubicin 14-17 nuclear factor kappa B subunit 1 Homo sapiens 163-172 34488792-6 2021 Interestingly, Nano-DOX also induced NF-kappaB-dependent RAGE expression in the tumor cells and thus reinforced HMGB1"s action thereon. Doxorubicin 20-23 nuclear factor kappa B subunit 1 Homo sapiens 37-46 34488792-11 2021 CONCLUSIONS: PD-L1/PD-1 upregulation mediated by autocrine and paracrine activation of the HMGB1/RAGE/NF-kappaB signaling is a key response of lung cancer cells and their TAMs to stress, which can be induced by Nano-DOX. Doxorubicin 216-219 nuclear factor kappa B subunit 1 Homo sapiens 102-111 34589399-0 2021 Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-kappaB and RAS/RAF/MEK/ERK signaling pathway. Doxorubicin 73-76 nuclear factor kappa B subunit 1 Homo sapiens 168-177 34589399-14 2021 What" more, for the first time, we also found miR34a combined with Dox could obviously inhibit the expression of Snail through suppressing Notch/NF-kappaB and RAS/RAF/MEK/ERK pathway in MCF-7/A cells. Doxorubicin 67-70 nuclear factor kappa B subunit 1 Homo sapiens 145-154 33425912-0 2020 EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-kappaB/MDM2/p53 Pathway. Doxorubicin 39-51 nuclear factor kappa B subunit 1 Homo sapiens 74-83 35052641-4 2022 PKD1 expression in acinar cells affects their survival and mediates ADM, which is in part due to the PKD1 target NF-kappaB. Doxorubicin 68-71 nuclear factor kappa B subunit 1 Homo sapiens 113-122 33425912-9 2020 Western blot in SW780 cells also confirmed that the combined use of EGCG and DOX caused significant increase in p53, p21, and cleaved-PARP expression, and induced significant inhibition in phosphorylated NF-kappaB and MDM2. Doxorubicin 77-80 nuclear factor kappa B subunit 1 Homo sapiens 204-213 35346012-6 2022 It has been shown that regulation of NF-kappaB and oxidative stress signaling pathways by DG is beneficial against cardiotoxicity induced by chemotherapeutic agents such as doxorubicin. Doxorubicin 173-184 nuclear factor kappa B subunit 1 Homo sapiens 37-46 33766750-9 2021 LncRNAs can drive DOX resistance via activating pathways such as NF-kappaB, PI3K/Akt, Wnt, and FOXC2. Doxorubicin 18-21 nuclear factor kappa B subunit 1 Homo sapiens 65-74 33536192-6 2021 When Didox was used in combination with doxorubicin, we observed significant downregulation of NF-kappaB proteins accompanied by reduced TNBC cell proliferation. Doxorubicin 40-51 nuclear factor kappa B subunit 1 Homo sapiens 95-104 33771682-0 2021 Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-kappaB/P65 pathway. Doxorubicin 23-33 nuclear factor kappa B subunit 1 Homo sapiens 136-145 33425912-8 2020 Further mechanistic studies determined that the combination of DOX and EGCG inhibited phosphorylated NF-kappaB and MDM2 expression, and up-regulated p53 expression in tumor, as assessed by western blot and immunohistochemistry. Doxorubicin 63-66 nuclear factor kappa B subunit 1 Homo sapiens 101-110 33425912-12 2020 EGCG enhanced the anti-tumor effect of DOX in bladder cancer via NF-kappaB/MDM2/p53 pathway, suggesting the potential clinical application against bladder cancer patients. Doxorubicin 39-42 nuclear factor kappa B subunit 1 Homo sapiens 65-74 32685149-8 2020 Doxorubicin and cyclophosphamide (CP), which are included in the current treatment regimen for MCL, enhance the NF-kappaB activity and increase CD83 expression on MCL cell lines. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 112-121 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. Doxorubicin 161-172 nuclear factor kappa B subunit 1 Homo sapiens 10-19 32774731-0 2020 Apatinib-induced NF-kappaB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. Doxorubicin 90-101 nuclear factor kappa B subunit 1 Homo sapiens 17-26 32774731-7 2020 Importantly, it was found that followed by DOX treatment, apatinib could inhibit NF-kappaB signaling pathways, which have been validated to increase ROS production and reverse DOX resistance. Doxorubicin 43-46 nuclear factor kappa B subunit 1 Homo sapiens 81-90 32774731-7 2020 Importantly, it was found that followed by DOX treatment, apatinib could inhibit NF-kappaB signaling pathways, which have been validated to increase ROS production and reverse DOX resistance. Doxorubicin 176-179 nuclear factor kappa B subunit 1 Homo sapiens 81-90 32461377-0 2020 Long noncoding RNA lnc-LOC645166 promotes adriamycin resistance via NF-kappaB/GATA3 axis in breast cancer. Doxorubicin 42-52 nuclear factor kappa B subunit 1 Homo sapiens 68-77 32461377-7 2020 Together, the present study suggested that lncRNA LOC645166 mediated adriamycin chemoresistance in breast cancer by regulating GATA3 via NF-kappaB. Doxorubicin 69-79 nuclear factor kappa B subunit 1 Homo sapiens 137-146 31837803-8 2020 Forth, dexrazoxane attenuated doxorubicin-induced inflammation and necroptosis by the inhibition of p38MAPK/NF-kappaB pathways. Doxorubicin 30-41 nuclear factor kappa B subunit 1 Homo sapiens 108-117 31412018-0 2019 Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-kappaB Pathway. Doxorubicin 16-27 nuclear factor kappa B subunit 1 Homo sapiens 99-108 31412018-10 2019 CONCLUSIONS Irisin can potentiate the cytotoxicity of doxorubicin in PC cells without increasing cardiotoxicity, possibly through inactivating the PI3K/AKT/NF-kappaB signaling pathway. Doxorubicin 54-65 nuclear factor kappa B subunit 1 Homo sapiens 156-165 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. Doxorubicin 161-172 nuclear factor kappa B subunit 1 Homo sapiens 190-199 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. Doxorubicin 234-245 nuclear factor kappa B subunit 1 Homo sapiens 10-19 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. Doxorubicin 234-245 nuclear factor kappa B subunit 1 Homo sapiens 190-199 30940449-8 2019 Furthermore, SENP2 overexpression-induced sensitivity of MCF-7/adr cells to doxorubicin is drastically abrogated when treated with NF-kappaB pathway activator, thus establishing a causal link between SENP2-suppressed NF-kappaB pathway and enhanced doxorubicin sensitivity in breast cancer cells. Doxorubicin 76-87 nuclear factor kappa B subunit 1 Homo sapiens 131-140 30940449-8 2019 Furthermore, SENP2 overexpression-induced sensitivity of MCF-7/adr cells to doxorubicin is drastically abrogated when treated with NF-kappaB pathway activator, thus establishing a causal link between SENP2-suppressed NF-kappaB pathway and enhanced doxorubicin sensitivity in breast cancer cells. Doxorubicin 76-87 nuclear factor kappa B subunit 1 Homo sapiens 217-226 30940449-8 2019 Furthermore, SENP2 overexpression-induced sensitivity of MCF-7/adr cells to doxorubicin is drastically abrogated when treated with NF-kappaB pathway activator, thus establishing a causal link between SENP2-suppressed NF-kappaB pathway and enhanced doxorubicin sensitivity in breast cancer cells. Doxorubicin 248-259 nuclear factor kappa B subunit 1 Homo sapiens 131-140 30940449-8 2019 Furthermore, SENP2 overexpression-induced sensitivity of MCF-7/adr cells to doxorubicin is drastically abrogated when treated with NF-kappaB pathway activator, thus establishing a causal link between SENP2-suppressed NF-kappaB pathway and enhanced doxorubicin sensitivity in breast cancer cells. Doxorubicin 248-259 nuclear factor kappa B subunit 1 Homo sapiens 217-226 30503721-4 2019 KEY FINDINGS: Data showed that doxorubicin + geopropolis diminished IL-6 secretion, stimulated TNF-alpha and IL-10 production, TLR-4 and CD80 expression, NF-kappaB and autophagy pathway, as well as the bactericidal activity. Doxorubicin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 154-163 30817976-6 2019 Doxorubicin treatment modified the cellular levels of NF-kappaB and the expression of AKR7A2. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 54-63 27878697-3 2017 METHODS AND MATERIALS: The NFkappaB pathway by siRNAP65 and JSH-23 as a translocational inhibitor of NFkappaBP65 in the doxorubicin-resistant MCF-7 (MCF-7/Dox) and MCF-7 cells was blocked. Doxorubicin 120-131 nuclear factor kappa B subunit 1 Homo sapiens 27-35 30243823-3 2018 In this report, CB5005 peptide, designed for its dual function in cell membrane penetration and NF-kappaB inhibition, was conjugated to PEGylated liposomes loaded with doxorubicin (CB5005-LS/DOX) or a fluorescent dye (CB5005-LS/dye). Doxorubicin 168-179 nuclear factor kappa B subunit 1 Homo sapiens 96-105 30274235-5 2018 Finally, FHC knock-down in K562 and SKOV3 cancer cell lines resulted in an improved cell viability following doxorubicin or cisplatin treatment, being counteracted by the transient expression of inhibitory of NF-kappaB, IkappaBalpha. Doxorubicin 109-120 nuclear factor kappa B subunit 1 Homo sapiens 209-218 30245930-9 2018 The overall result suggested that alteration in protein level and location of survivin and NF-kappaB by miR-34a, miR-320a, miR-146a and miR-542, remarkably influenced the synergistic enhancement of combined MBIC and doxorubicin in treatment of aggressive and less aggressive human breast cancer cell lines. Doxorubicin 216-227 nuclear factor kappa B subunit 1 Homo sapiens 91-100 29943786-4 2018 These spherical CST/DOX NPs can improve the water-solubility of CST, reduce the dosage of DOX, and therefore significantly enhance cellular drug accumulation by activating heat shock factor 1 (HSF-1) and inhibiting NF-kappaB to depress P-gp expression, which results in apoptosis and autophagy of DOX resistant cells through the ROS/JNK signaling pathway. Doxorubicin 20-23 nuclear factor kappa B subunit 1 Homo sapiens 215-224 33445276-6 2018 The MTT assay and flow cytometry indicated that it could increase the therapeutic efficacy of poly(amino acid)-doxorubicin, and Western blot results showed that bortezomib and poly(amino acid)-doxorubicin can synergistically diminish NFkappaB expression. Doxorubicin 193-204 nuclear factor kappa B subunit 1 Homo sapiens 234-242 28752270-0 2017 Combination treatment with dendrosomal nanocurcumin and doxorubicin improves anticancer effects on breast cancer cells through modulating CXCR4/NF-kappaB/Smo regulatory network. Doxorubicin 56-67 nuclear factor kappa B subunit 1 Homo sapiens 144-153 30396468-0 2018 The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF-kappaB/Snail/Bcl-2 pathway. Doxorubicin 63-73 nuclear factor kappa B subunit 1 Homo sapiens 78-87 30396468-6 2018 Therefore, we suggest the CD44v16 could induce the K562 cell acquired with resistance to adriamycin via NF-kappaB/Snail/Bcl-2 pathway, which paved the way for further study the function of CD44v16 in drug resistance. Doxorubicin 89-99 nuclear factor kappa B subunit 1 Homo sapiens 104-113 29779937-8 2018 RESULTS: BCL-2, BAX and NF-KappaB showed decreased expression in MCF7 bulk cancer cells after DOX treatment whereas only BCL-2 and BAX showed decreased expression in MDA-MB-231 bulk cancer cells. Doxorubicin 94-97 nuclear factor kappa B subunit 1 Homo sapiens 24-33 28684738-9 2017 DOX induced activation of MAPK; p38 and JNK and increased expression of NF-kappaB. Doxorubicin 0-3 nuclear factor kappa B subunit 1 Homo sapiens 72-81 27878697-3 2017 METHODS AND MATERIALS: The NFkappaB pathway by siRNAP65 and JSH-23 as a translocational inhibitor of NFkappaBP65 in the doxorubicin-resistant MCF-7 (MCF-7/Dox) and MCF-7 cells was blocked. Doxorubicin 155-158 nuclear factor kappa B subunit 1 Homo sapiens 27-35 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 61-72 nuclear factor kappa B subunit 1 Homo sapiens 27-35 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 115-118 nuclear factor kappa B subunit 1 Homo sapiens 27-35 26842876-6 2016 Treatment of preexisting CSCs with a genotoxic drug combination (5-fluorouracil, doxorubicin, and cyclophosphamide) generated an NFkappaB-IL6-dependent inflammatory environment that imparted stemness to nonstem cancer cells, induced multidrug resistance, and enhanced the migration potential of CSCs. Doxorubicin 81-92 nuclear factor kappa B subunit 1 Homo sapiens 129-137 28036258-0 2017 Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappaB and Btk. Doxorubicin 33-44 nuclear factor kappa B subunit 1 Homo sapiens 120-129 28036258-4 2017 Our results indicate that EBV influences cell survival via an autocrine mechanism whereby EBNA2 increases CCL3 and CCL4, which in turn activate the Btk and NF-kappaB pathways, contributing to doxorubicin resistance of B lymphoma cells. Doxorubicin 192-203 nuclear factor kappa B subunit 1 Homo sapiens 156-165 28036258-6 2017 Based on these findings, we propose that a pathway involving EBNA2/Btk/NF-kappaB/CCL3/CCL4 plays a key role in doxorubicin resistance, and therefore, inhibition of specific components of this pathway may sensitize lymphoma cells to doxorubicin. Doxorubicin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 71-80 28036258-6 2017 Based on these findings, we propose that a pathway involving EBNA2/Btk/NF-kappaB/CCL3/CCL4 plays a key role in doxorubicin resistance, and therefore, inhibition of specific components of this pathway may sensitize lymphoma cells to doxorubicin. Doxorubicin 232-243 nuclear factor kappa B subunit 1 Homo sapiens 71-80 29617099-7 2017 Further studies in MDA-MB-231 cells demonstrated that CARF also inhibited pro-inflammatory IL-6 secretion and NF kappaB transcriptional activity while DOX stimulated both IL-6 and NF kappa-B activity. Doxorubicin 151-154 nuclear factor kappa B subunit 1 Homo sapiens 180-190 27741396-6 2016 Moreover, NASFs significantly impeded NF-kappaB activation in cells stimulated with damage-associated molecular pattern molecules (DAMPs) released from doxorubicin killed cancer cells. Doxorubicin 152-163 nuclear factor kappa B subunit 1 Homo sapiens 38-47 27731405-5 2016 Furthermore, DOX/RES-loaded NPS could overcome DOX resistance by inhibiting the expression of drug resistance-related protein such as P-gp, MRP-1 and BCRP, and induce apoptosis through down-regulating the expression of NF-kappaB and BCL-2. Doxorubicin 13-16 nuclear factor kappa B subunit 1 Homo sapiens 219-228 27731405-5 2016 Furthermore, DOX/RES-loaded NPS could overcome DOX resistance by inhibiting the expression of drug resistance-related protein such as P-gp, MRP-1 and BCRP, and induce apoptosis through down-regulating the expression of NF-kappaB and BCL-2. Doxorubicin 47-50 nuclear factor kappa B subunit 1 Homo sapiens 219-228 27784426-6 2016 Results: After being treated by adriamycin, hepatoma cells showed increased expression of P-gp and an increased level of NF-kappaB phosphorylation. Doxorubicin 32-42 nuclear factor kappa B subunit 1 Homo sapiens 121-130 26969380-0 2016 Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2alpha-ERK1/2 pathway-mediated NF-kappaB activation. Doxorubicin 49-52 nuclear factor kappa B subunit 1 Homo sapiens 124-133 25837271-0 2015 Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling. Doxorubicin 23-34 nuclear factor kappa B subunit 1 Homo sapiens 107-117 27960162-0 2016 The mTORC2/Akt/NFkappaB Pathway-Mediated Activation of TRPC6 Participates in Adriamycin-Induced Podocyte Apoptosis. Doxorubicin 77-87 nuclear factor kappa B subunit 1 Homo sapiens 15-23 25400040-6 2015 Moreover, overexpression of p28(GANK) attenuated the capability of NF-kappaB binding to the target gene IkappaBalpha promoter, but also weakened adriamycin-induced NF-kappaB pro-apoptotic gene Fas and FasL expression, which subsequently made p53-deficient tumor cells resistance to adriamycin. Doxorubicin 145-155 nuclear factor kappa B subunit 1 Homo sapiens 164-173 32262864-2 2015 Pyrrolidinedithiocarbamate (PDTC), a nuclear-factor-kappa B (NF-kappaB) inhibitor, was demonstrated to be able to overcome chemoresistance and enhance doxorubicin (DOX) efficacy as a chemotherapeutic sensitizer. Doxorubicin 151-162 nuclear factor kappa B subunit 1 Homo sapiens 37-59 32262864-2 2015 Pyrrolidinedithiocarbamate (PDTC), a nuclear-factor-kappa B (NF-kappaB) inhibitor, was demonstrated to be able to overcome chemoresistance and enhance doxorubicin (DOX) efficacy as a chemotherapeutic sensitizer. Doxorubicin 151-162 nuclear factor kappa B subunit 1 Homo sapiens 61-70 32262864-2 2015 Pyrrolidinedithiocarbamate (PDTC), a nuclear-factor-kappa B (NF-kappaB) inhibitor, was demonstrated to be able to overcome chemoresistance and enhance doxorubicin (DOX) efficacy as a chemotherapeutic sensitizer. Doxorubicin 164-167 nuclear factor kappa B subunit 1 Homo sapiens 37-59 32262864-2 2015 Pyrrolidinedithiocarbamate (PDTC), a nuclear-factor-kappa B (NF-kappaB) inhibitor, was demonstrated to be able to overcome chemoresistance and enhance doxorubicin (DOX) efficacy as a chemotherapeutic sensitizer. Doxorubicin 164-167 nuclear factor kappa B subunit 1 Homo sapiens 61-70 26169986-15 2015 Cucurbitacin D decreases cell proliferation and induces apoptosis by inhibiting Stat3 and NF-kappaB signaling in doxorubicin-resistant breast cancer cells. Doxorubicin 113-124 nuclear factor kappa B subunit 1 Homo sapiens 90-99 25704882-11 2015 Accordingly, inhibitors of NF-kappaB and of the NF-kappaB/p53-regulated anti-apoptotic protein survivin significantly sensitize colon carcinoma cells expressing wild-type HDAC2 to apoptosis induced by the genotoxin doxorubicin. Doxorubicin 215-226 nuclear factor kappa B subunit 1 Homo sapiens 27-36 25704882-11 2015 Accordingly, inhibitors of NF-kappaB and of the NF-kappaB/p53-regulated anti-apoptotic protein survivin significantly sensitize colon carcinoma cells expressing wild-type HDAC2 to apoptosis induced by the genotoxin doxorubicin. Doxorubicin 215-226 nuclear factor kappa B subunit 1 Homo sapiens 48-57 27055634-3 2016 NF-kappaB gene transcription in human HepG2 cells was intervened by specific siRNA with/without doxorubicin treatment. Doxorubicin 96-107 nuclear factor kappa B subunit 1 Homo sapiens 0-9 27055634-9 2016 After the cells were transfected with siRNA, the NF-kappaB expression was down-regulated at mRNA or protein level with higher sensitivity to doxorubicin. Doxorubicin 141-152 nuclear factor kappa B subunit 1 Homo sapiens 49-58 26668505-8 2015 After treatment of HepG2 cells with different doses of doxorubicin, the expression of NF-kappaB/p65, P-p65, and especially P-gp were dose-dependently upregulated. Doxorubicin 55-66 nuclear factor kappa B subunit 1 Homo sapiens 86-95 26169986-0 2015 Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-kappaB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Doxorubicin 102-113 nuclear factor kappa B subunit 1 Homo sapiens 79-88 25401416-7 2014 Transcriptome data were confirmed for 12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) were synergistically up-regulated after Doxo+TNFalpha and dependent both on p53 and NFkappaB. Doxorubicin 159-163 nuclear factor kappa B subunit 1 Homo sapiens 203-211 25478729-0 2015 Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-kappaB pathway. Doxorubicin 15-25 nuclear factor kappa B subunit 1 Homo sapiens 130-139 25401416-3 2014 Transcriptome analyses upon single or combined treatments with doxorubicin (Doxo, 1.5muM) and the NFkappaB inducer TNF-alpha (TNFalpha, 5ng/ml) revealed 432 up-regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFalpha treatment. Doxorubicin 236-240 nuclear factor kappa B subunit 1 Homo sapiens 98-106 25550688-6 2014 Furthermore, the property of NF-kappaB activation shared by DOX and PTX was not identical. Doxorubicin 60-63 nuclear factor kappa B subunit 1 Homo sapiens 29-38 25550688-7 2014 An attempt made in the present study demonstrated that the acquired resistance to DOX was via or partially via NF-kappaB activation but not its upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-kappaB pathway. Doxorubicin 82-85 nuclear factor kappa B subunit 1 Homo sapiens 111-120 25550688-7 2014 An attempt made in the present study demonstrated that the acquired resistance to DOX was via or partially via NF-kappaB activation but not its upstream receptor TLR4, while PTX can induce the drug resistance via TLR4-NF-kappaB pathway. Doxorubicin 82-85 nuclear factor kappa B subunit 1 Homo sapiens 218-227 23898080-8 2013 Doxorubicin induced activity of p53 and NF-kappaB. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 40-49 24858801-2 2014 The results showed that CXCL12 could enhance the resistance of K562 cells to adriamycin (ADM) by increasing the expression of CXCR4, up-regulating the downstream PI3K/Akt pathway, and promoting translocation of NF-kappaB dimers into nucleus and subsequently decreasing the expression of apoptosis-related proteins in K562 cells. Doxorubicin 89-92 nuclear factor kappa B subunit 1 Homo sapiens 211-220 24565101-7 2014 RESULTS: Both TNFalpha and doxorubicin treatment activated the NF-kappaB signaling pathway in HCC cells. Doxorubicin 27-38 nuclear factor kappa B subunit 1 Homo sapiens 63-72 24565101-13 2014 CONCLUSIONS: These data suggest that miR-26b suppresses NF-kappaB signaling and thereby sensitized HCC cells to the doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Doxorubicin 116-127 nuclear factor kappa B subunit 1 Homo sapiens 56-65 24245692-0 2014 Suppression of NF-kappaB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer. Doxorubicin 108-118 nuclear factor kappa B subunit 1 Homo sapiens 15-24 24245692-9 2014 The critical role of NF-kappaB was further confirmed by using PDTC, a NF-kappaB inhibitor, which significantly increased apoptosis induction by the combination of GA and ADM and inhibited ADM-induced ABCB1 upregulation. Doxorubicin 170-173 nuclear factor kappa B subunit 1 Homo sapiens 21-30 24245692-9 2014 The critical role of NF-kappaB was further confirmed by using PDTC, a NF-kappaB inhibitor, which significantly increased apoptosis induction by the combination of GA and ADM and inhibited ADM-induced ABCB1 upregulation. Doxorubicin 170-173 nuclear factor kappa B subunit 1 Homo sapiens 70-79 24245692-10 2014 Importantly, our results indicated that the combination of GA and ADM exerted enhanced anti-tumor effects on A549 xenograft models through inhibiting NF-kappaB and P-glycoprotein, and attenuated ADM-induced cardiotoxicity. Doxorubicin 66-69 nuclear factor kappa B subunit 1 Homo sapiens 150-159 23792430-6 2013 PN also exhibited inhibitory effect on NF-kappaB activation in A549/DOX cells, suggesting that inhibition of NF-kappaB was involved in attenuating P-gp expression by PN. Doxorubicin 68-71 nuclear factor kappa B subunit 1 Homo sapiens 39-48 23792430-6 2013 PN also exhibited inhibitory effect on NF-kappaB activation in A549/DOX cells, suggesting that inhibition of NF-kappaB was involved in attenuating P-gp expression by PN. Doxorubicin 68-71 nuclear factor kappa B subunit 1 Homo sapiens 109-118 24715151-0 2014 Doxorubicin induces drug resistance and expression of the novel CD44st via NF-kappaB in human breast cancer MCF-7 cells. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 75-84 24715151-7 2014 In the present study, we verified that MCF-7 cells subjected to drug pressure develop multidrug resistance to doxorubicin, and the expression levels of multidrug resistance protein 1 (MDR1), CD44st and nuclear factor-kappaB (NF-kappaB) mRNA and protein were gradually upregulated in a dose-dependent manner in MCF-7 cells treated with doxorubicin. Doxorubicin 335-346 nuclear factor kappa B subunit 1 Homo sapiens 225-234 24495648-0 2014 Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss. Doxorubicin 40-51 nuclear factor kappa B subunit 1 Homo sapiens 134-144 23892407-0 2013 Doxorubicin induces atypical NF-kappaB activation through c-Abl kinase activity in breast cancer cells. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 29-38 23892407-2 2013 We studied the signaling pathway activated by doxorubicin (DOX) leading to NF-kappaB activation in breast cancer cells. Doxorubicin 46-57 nuclear factor kappa B subunit 1 Homo sapiens 75-84 23892407-2 2013 We studied the signaling pathway activated by doxorubicin (DOX) leading to NF-kappaB activation in breast cancer cells. Doxorubicin 59-62 nuclear factor kappa B subunit 1 Homo sapiens 75-84 23892407-7 2013 RESULTS: We found a correlation between sensitivity to DOX and amplitude of NF-kappaB activation. Doxorubicin 55-58 nuclear factor kappa B subunit 1 Homo sapiens 76-85 23892407-8 2013 In cells least sensitive to DOX, NF-kappaB remained activated for longer time (T47D and MBCDF). Doxorubicin 28-31 nuclear factor kappa B subunit 1 Homo sapiens 33-42 23892407-12 2013 In DOX-resistant cells, Imatinib treatment reduced IkappaBalpha tyrosine phosphorylation and NF-kappaB activity. Doxorubicin 3-6 nuclear factor kappa B subunit 1 Homo sapiens 93-102 23892407-14 2013 Overexpression of c-Abl K290R in T47D and MBCDF cells reduced basal and DOX-induced NF-kappaB activation as well as IkappaBalpha tyrosine phosphorylation. Doxorubicin 72-75 nuclear factor kappa B subunit 1 Homo sapiens 84-93 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. Doxorubicin 51-62 nuclear factor kappa B subunit 1 Homo sapiens 71-80 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. Doxorubicin 51-62 nuclear factor kappa B subunit 1 Homo sapiens 114-123 21245867-0 2011 The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-kappaB. Doxorubicin 82-93 nuclear factor kappa B subunit 1 Homo sapiens 130-151 23725146-0 2013 Effect of Bcl-2 on apoptosis and transcription factor NF-kappaB activation induced by adriamycin in bladder carcinoma BIU87 cells. Doxorubicin 86-96 nuclear factor kappa B subunit 1 Homo sapiens 54-63 23725146-9 2013 These results suggest that the overexpression of Bcl-2 renders human bladder carcinoma cells resistant to adriamycin -induced cytotoxicity and there is a link between Bcl-2 and the NF-kappaB signaling pathway in the suppression of apoptosis. Doxorubicin 106-116 nuclear factor kappa B subunit 1 Homo sapiens 181-190 22134636-0 2012 Pro-oxidant and antioxidant effects of N-acetylcysteine regulate doxorubicin-induced NF-kappa B activity in leukemic cells. Doxorubicin 65-76 nuclear factor kappa B subunit 1 Homo sapiens 85-95 22134636-5 2012 In this study, we systematically evaluated the effect of Dox-induced ROS on the NF-kappaB pathway in a pediatric acute lymphoblastic leukemia (ALL) cell line by measuring the thiol-based oxidative modifications of redox-sensitive proteins within the pathway. Doxorubicin 57-60 nuclear factor kappa B subunit 1 Homo sapiens 80-89 22134636-6 2012 We report a functional consequence of NAC supplementation during doxorubicin (Dox) chemotherapy administration via the NF-kappa B (NF-kappaB) signal transduction pathway. Doxorubicin 65-76 nuclear factor kappa B subunit 1 Homo sapiens 119-129 22134636-6 2012 We report a functional consequence of NAC supplementation during doxorubicin (Dox) chemotherapy administration via the NF-kappa B (NF-kappaB) signal transduction pathway. Doxorubicin 65-76 nuclear factor kappa B subunit 1 Homo sapiens 131-140 22134636-6 2012 We report a functional consequence of NAC supplementation during doxorubicin (Dox) chemotherapy administration via the NF-kappa B (NF-kappaB) signal transduction pathway. Doxorubicin 78-81 nuclear factor kappa B subunit 1 Homo sapiens 119-129 22134636-6 2012 We report a functional consequence of NAC supplementation during doxorubicin (Dox) chemotherapy administration via the NF-kappa B (NF-kappaB) signal transduction pathway. Doxorubicin 78-81 nuclear factor kappa B subunit 1 Homo sapiens 131-140 22134636-7 2012 The ability of NAC to alter Dox-induced NF-kappaB activity is contingent on the ROS-mediated S-glutathionylation of IKK-beta. Doxorubicin 28-31 nuclear factor kappa B subunit 1 Homo sapiens 40-49 22134636-8 2012 Moreover, the NAC-dependent alteration of intracellular glutathione redox balance, through pro-oxidant and antioxidant mechanisms, can be exploited to either promote or inhibit Dox-induced NF-kappaB activity in an NAC-concentration-dependent manner. Doxorubicin 177-180 nuclear factor kappa B subunit 1 Homo sapiens 189-198 22134636-9 2012 We developed an electron-transfer-based computational model that predicts the effect of NAC pretreatment on Dox-induced NF-kappaB signaling for a range of NAC and Dox treatment combinations. Doxorubicin 108-111 nuclear factor kappa B subunit 1 Homo sapiens 120-129 22134636-9 2012 We developed an electron-transfer-based computational model that predicts the effect of NAC pretreatment on Dox-induced NF-kappaB signaling for a range of NAC and Dox treatment combinations. Doxorubicin 163-166 nuclear factor kappa B subunit 1 Homo sapiens 120-129 21387297-0 2012 Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-kappaB via targeting of Mre11. Doxorubicin 52-63 nuclear factor kappa B subunit 1 Homo sapiens 101-110 21387297-4 2012 Here, we report that JG3 inhibits NF-kappaB activation by specifically antagonizing the doxorubicin-triggered Ataxia-telangiectasia-mutated kinase (ATM) and the sequential MEK/ERK/p90Rsk/IKK signaling pathway but does not interfere with TNF-alpha-mediated NF-kappaB activation. Doxorubicin 88-99 nuclear factor kappa B subunit 1 Homo sapiens 34-43 21040711-8 2011 Also, NFkappaB was found overstimulated in cisplatin-resistant C6 cells, and treatment of GBMs with NFkappaB inhibitors overcame cisplatin resistance besides potentiating the effects of the chemotherapeutics, cisplatin and doxorubicin. Doxorubicin 223-234 nuclear factor kappa B subunit 1 Homo sapiens 6-14 21040711-8 2011 Also, NFkappaB was found overstimulated in cisplatin-resistant C6 cells, and treatment of GBMs with NFkappaB inhibitors overcame cisplatin resistance besides potentiating the effects of the chemotherapeutics, cisplatin and doxorubicin. Doxorubicin 223-234 nuclear factor kappa B subunit 1 Homo sapiens 100-108 21132265-0 2011 Agaricus blazei Murill enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells by NFkappaB-mediated increase of intracellular doxorubicin accumulation. Doxorubicin 32-43 nuclear factor kappa B subunit 1 Homo sapiens 105-113 21132265-0 2011 Agaricus blazei Murill enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells by NFkappaB-mediated increase of intracellular doxorubicin accumulation. Doxorubicin 149-160 nuclear factor kappa B subunit 1 Homo sapiens 105-113 23621869-0 2013 Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-kappaB signaling inhibition. Doxorubicin 54-64 nuclear factor kappa B subunit 1 Homo sapiens 175-184 23023936-10 2013 Results from western blotting showed that curcuminoids could inhibit the adriamycin-induced increase of NF-kappaB nuclear translocation and activation. Doxorubicin 73-83 nuclear factor kappa B subunit 1 Homo sapiens 104-113 23383209-0 2013 Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. Doxorubicin 18-29 nuclear factor kappa B subunit 1 Homo sapiens 84-93 23383209-5 2013 Significantly, imatinib prevents intrinsic resistance by promoting doxorubicin-mediated NF-kappaB/p65 nuclear localization and repression of NF-kappaB targets in a STAT3-dependent manner, and by preventing activation of a novel STAT3/HSP27/p38/Akt survival pathway. Doxorubicin 67-78 nuclear factor kappa B subunit 1 Homo sapiens 88-97 22448708-0 2012 Doxorubicin-induced neurotoxicity is attenuated by a 43-kD protein from the leaves of Cajanus indicus L. via NF-kappaB and mitochondria dependent pathways. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 109-118 22448708-8 2012 In addition, Dox markedly increased nuclear factor kappa B (NF-kappaB) nuclear translocation in association with IKKalpha/beta phosphorylation and IkappaBalpha degradation. Doxorubicin 13-16 nuclear factor kappa B subunit 1 Homo sapiens 36-58 22448708-8 2012 In addition, Dox markedly increased nuclear factor kappa B (NF-kappaB) nuclear translocation in association with IKKalpha/beta phosphorylation and IkappaBalpha degradation. Doxorubicin 13-16 nuclear factor kappa B subunit 1 Homo sapiens 60-69 21387297-4 2012 Here, we report that JG3 inhibits NF-kappaB activation by specifically antagonizing the doxorubicin-triggered Ataxia-telangiectasia-mutated kinase (ATM) and the sequential MEK/ERK/p90Rsk/IKK signaling pathway but does not interfere with TNF-alpha-mediated NF-kappaB activation. Doxorubicin 88-99 nuclear factor kappa B subunit 1 Homo sapiens 256-265 21245867-7 2011 On the other hand, monoHER pretreatment significantly reduced doxorubicin-induced NF-kappaB activation. Doxorubicin 62-73 nuclear factor kappa B subunit 1 Homo sapiens 82-91 21245867-8 2011 CONCLUSION: These results suggest that reduction of doxorubicin-induced NF-kappaB activation by monoHER, which sensitises cancer cells to apoptosis, is involved in the chemosensitising effect of monoHER in human liposarcoma cells. Doxorubicin 52-63 nuclear factor kappa B subunit 1 Homo sapiens 72-81 21184742-0 2011 RPAP3 enhances cytotoxicity of doxorubicin by impairing NF-kappa B pathway. Doxorubicin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 56-66 21184742-3 2011 In this study, we revealed that RPAP3 (RNA polymerase II-associated protein 3) possesses an activity to bind with NEMO and to inhibit the ubiquitination of NEMO and that RPAP3 enhances doxorubicin-induced cell death in breast cancer cell line T-47D through the marked impairment of NF-kappaB pathway. Doxorubicin 185-196 nuclear factor kappa B subunit 1 Homo sapiens 282-291 20229271-8 2011 RESULTS: Compared with sensitive MCF-7 cells, MDR1 and its transcription factors c-Jun and NF-kappaB were up-regulated at both mRNA level (P < 0.01) and protein level (P < 0.01) by treatment with 0.05 mug/ml doxorubicin for 7 days. Doxorubicin 214-225 nuclear factor kappa B subunit 1 Homo sapiens 91-100 20798686-5 2011 On the other hand, we also found that the adriamycin-activated NF-kappaB directly binds the promoter of miR-448 suppressing its transcription, suggesting a positive feedback loop between NF-kappaB and miR-448. Doxorubicin 42-52 nuclear factor kappa B subunit 1 Homo sapiens 63-72 20798686-5 2011 On the other hand, we also found that the adriamycin-activated NF-kappaB directly binds the promoter of miR-448 suppressing its transcription, suggesting a positive feedback loop between NF-kappaB and miR-448. Doxorubicin 42-52 nuclear factor kappa B subunit 1 Homo sapiens 187-196 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 47-58 nuclear factor kappa B subunit 1 Homo sapiens 145-154 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 47-58 nuclear factor kappa B subunit 1 Homo sapiens 282-291 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 171-182 nuclear factor kappa B subunit 1 Homo sapiens 145-154 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 171-182 nuclear factor kappa B subunit 1 Homo sapiens 282-291 20229271-11 2011 CONCLUSION: Celecoxib effectively prevents the development of chemoresistance in breast cancer cell line MCF-7 induced by doxorubicin, which was partly involved in inhibiting the expression and DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB and downstream expression and function of P-gp. Doxorubicin 122-133 nuclear factor kappa B subunit 1 Homo sapiens 257-266 20624391-0 2010 Elevation of cyclic AMP causes an imbalance between NF-kappaB and p53 in NALM-6 cells treated by doxorubicin. Doxorubicin 97-108 nuclear factor kappa B subunit 1 Homo sapiens 52-61 21187919-8 2010 Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB. Doxorubicin 47-57 nuclear factor kappa B subunit 1 Homo sapiens 117-126 21187919-8 2010 Furthermore, the combination of MNP-Fe3O4 with adriamycin or daunorubicin increased p53 protein levels and decreased NF-kappaB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe3O4 could enhance the effect of chemotherapeutic drugs on p53 and NF-kappaB. Doxorubicin 47-57 nuclear factor kappa B subunit 1 Homo sapiens 274-283 20624391-5 2010 The present study also shows that elevation of cAMP prolongs the phosphorylation of IkappaB and subsequent activation of NF-kappaB in doxorubicin treated NALM-6 cells in a proteasome-dependent manner. Doxorubicin 134-145 nuclear factor kappa B subunit 1 Homo sapiens 121-130 20624391-3 2010 We found that inhibition of NF-kappaB activation prevents the inhibitory effect of cAMP on doxorubicin-induced apoptosis. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 28-37 19898868-8 2010 Both mRNA and protein levels of NF-kappaB were up-regulated in the cells treated with doxorubicin only. Doxorubicin 86-97 nuclear factor kappa B subunit 1 Homo sapiens 32-41 19898868-10 2010 However, tetrandrine could markedly inhibit the doxorubicin-induced expression of NF-kappaB mRNA and protein. Doxorubicin 48-59 nuclear factor kappa B subunit 1 Homo sapiens 82-91 19898868-12 2010 CONCLUSION: In summary, tetrandrine can prevent doxorubicin-induced mdr1 mRNA/P-gp expression and P-gp functions in a dose-dependent manner through a mechanism that may involve inhibition of doxorubicin-induced NF-kappaB mRNA expression and protein activity. Doxorubicin 48-59 nuclear factor kappa B subunit 1 Homo sapiens 211-220 19646807-9 2010 At sub-apoptotic concentrations, BAY117082 and MG132 arrested cells in G2/M phase of the cell cycle and blocked doxorubicin-induced NFkappaB, which sensitized doxorubicin-resistant cells. Doxorubicin 112-123 nuclear factor kappa B subunit 1 Homo sapiens 132-140 19649704-6 2010 Anti-IL-8 or -FasL antibody, dominant negative TRAF6 (TRAF6-DN), or TRAF6 binding peptide (TRAF6-BP) inhibited doxorubicin-mediated late phase induction of NF-kappaB and diminished cell death. Doxorubicin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 156-165 20056115-6 2010 The combination of Rg3 (50 microM) with cisplatin (10 microM) and doxorubicin (2 microM) was also more effective in the inhibition of prostate cancer cell growth and NF-kappaB activity than those by the treatment of Rg3 or chemotherapeutics alone. Doxorubicin 66-77 nuclear factor kappa B subunit 1 Homo sapiens 166-175 19649704-0 2010 Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Doxorubicin 64-75 nuclear factor kappa B subunit 1 Homo sapiens 54-60 19649704-3 2010 In this report, we provide evidences that doxorubicin induced biphasic induction of nuclear factor kappaB (NF-kappaB) of immediate activation followed by decrease in the amount of RelA (p65) subunit possibly by inducing the activity of proteasome, but not proteases. Doxorubicin 42-53 nuclear factor kappa B subunit 1 Homo sapiens 99-105 19649704-3 2010 In this report, we provide evidences that doxorubicin induced biphasic induction of nuclear factor kappaB (NF-kappaB) of immediate activation followed by decrease in the amount of RelA (p65) subunit possibly by inducing the activity of proteasome, but not proteases. Doxorubicin 42-53 nuclear factor kappa B subunit 1 Homo sapiens 107-116 19649704-4 2010 Further induction of NF-kappaB was observed through interleukin 8 (IL-8), expressed by doxorubicin treatment. Doxorubicin 87-98 nuclear factor kappa B subunit 1 Homo sapiens 21-30 20124446-10 2010 Furthermore, V1810 reverses NF-kappaB activation induced by the genotoxic drugs melphalan and doxorubicin. Doxorubicin 94-105 nuclear factor kappa B subunit 1 Homo sapiens 28-37 19242952-6 2009 High basal expressions of multi-drug resistant protein and transglutaminase were found in Dox-resistant cells and inhibition of NF-kappaB decreased those amounts and also sensitized these cells by Doxorubicin. Doxorubicin 197-208 nuclear factor kappa B subunit 1 Homo sapiens 128-137 19242952-0 2009 Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. Doxorubicin 86-97 nuclear factor kappa B subunit 1 Homo sapiens 68-74 20102612-6 2010 Supporting this crosstalk, the activation of NF-kappaB by retinoids in T47D cells antagonizes the apoptosis triggered by the chemotherapeutic drugs etoposide, camptothecin or doxorubicin. Doxorubicin 175-186 nuclear factor kappa B subunit 1 Homo sapiens 45-54 19725919-5 2009 Chemotherapeutic drugs that intercalate into DNA and inhibit topoisomerase II such as Doxorubicin, Daunorubicin and Mitoxantrone stimulate NF-kappaB DNA binding and transcriptional activity prior to induction of cell death. Doxorubicin 86-97 nuclear factor kappa B subunit 1 Homo sapiens 139-148 19725919-6 2009 Importantly, specific inhibition of drug-induced NF-kappaB activation by IkappaBalpha-SR or RNA interference against p65 significantly reduces apoptosis upon treatment with Doxorubicin, Daunorubicin or Mitoxantrone. Doxorubicin 173-184 nuclear factor kappa B subunit 1 Homo sapiens 49-58 19834284-6 2009 Similar combination effects of obovatol with other chemotherapeutic agents (paclitaxel, cisplatin, and doxorubicin) on the inhibition of cell growth and NF-kappaB activity were also found. Doxorubicin 103-114 nuclear factor kappa B subunit 1 Homo sapiens 153-162 19746155-0 2009 Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. Doxorubicin 135-146 nuclear factor kappa B subunit 1 Homo sapiens 47-56 19746155-0 2009 Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. Doxorubicin 135-146 nuclear factor kappa B subunit 1 Homo sapiens 91-100 19746155-2 2009 In contrast, recent studies have proposed that, in response to doxorubicin, NF-kappaB can be pro-apoptotic through repression of anti-apoptotic target genes. Doxorubicin 63-74 nuclear factor kappa B subunit 1 Homo sapiens 76-85 19746155-4 2009 In this study, we further characterize the activation of NF-kappaB in response to doxorubicin and evaluate its role in chemotherapy-induced cell death in sarcoma cells where NF-kappaB is reported to be pro-apoptotic. Doxorubicin 82-93 nuclear factor kappa B subunit 1 Homo sapiens 57-66 19746155-5 2009 Doxorubicin treatment in U2OS cells induced canonical NF-kappaB activity as evidenced by increased nuclear accumulation of phosphorylated p65 at serine 536 and increased DNA-binding activity. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 54-63 19746155-8 2009 Furthermore, the combination of doxorubicin and canonical NF-kappaB inhibition with Compound A or siRNA to p65 resulted in decreased cell viability measured by trypan blue staining and MTS assay and increased apoptosis measured by cleaved poly (ADP-ribose) polymerase and cleaved caspase 3 when compared to doxorubicin alone. Doxorubicin 307-318 nuclear factor kappa B subunit 1 Homo sapiens 58-67 19746155-9 2009 Our results demonstrate that doxorubicin-induced canonical NF-kappaB activity associated with phosphorylated p65 is anti-apoptotic in its function and that doxorubicin-induced repression of anti-apoptotic genes occurs independent of p65. Doxorubicin 29-40 nuclear factor kappa B subunit 1 Homo sapiens 59-68 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 31-34 nuclear factor kappa B subunit 1 Homo sapiens 78-87 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 31-34 nuclear factor kappa B subunit 1 Homo sapiens 156-165 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 58-69 nuclear factor kappa B subunit 1 Homo sapiens 78-87 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 58-69 nuclear factor kappa B subunit 1 Homo sapiens 156-165 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 58-61 nuclear factor kappa B subunit 1 Homo sapiens 78-87 19242952-4 2009 We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappaB was transient and Dox-resistant cells showed high basal activity of NF-kappaB and expression of genes dependent on it. Doxorubicin 58-61 nuclear factor kappa B subunit 1 Homo sapiens 156-165 19242952-6 2009 High basal expressions of multi-drug resistant protein and transglutaminase were found in Dox-resistant cells and inhibition of NF-kappaB decreased those amounts and also sensitized these cells by Doxorubicin. Doxorubicin 90-93 nuclear factor kappa B subunit 1 Homo sapiens 128-137 19242952-7 2009 These observations collectively suggest that high NF-kappaB activity confers resistance to Doxorubicin and its inhibition potentiates apoptosis. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 50-59 19065652-3 2009 Doxorubicin, VP16 and the cytotoxic ligand TRAIL trigger NF-kappaB activation, whereas cisplatin and taxol have no impact on NF-kappaB activity. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 57-66 19065652-4 2009 Specific inhibition of NF-kappaB activation by overexpression of dominant-negative mutant IkappaBalpha-super-repressor does not alter cell death upon doxorubicin or VP16 treatment, although it prevents doxorubicin- or VP16-mediated NF-kappaB activation. Doxorubicin 202-213 nuclear factor kappa B subunit 1 Homo sapiens 23-32 19223549-7 2009 This XIAP-dependent event occurs in response to camptotechin or etoposide/VP16; however, XIAP is dispensable for activation of NF-kappaB by doxorubicin, which engages a MEK-ERK pathway to activate IKK. Doxorubicin 140-151 nuclear factor kappa B subunit 1 Homo sapiens 127-136 19252751-3 2009 The efficacy of conventional chemotherapeutic drugs, such as vincristine (VCR) and doxorubicine (DOX), may be enhanced with combined therapy based on NF-kappaB modulation. Doxorubicin 97-100 nuclear factor kappa B subunit 1 Homo sapiens 150-159 19035180-7 2008 RESULTS: After treatment with 0.6 microg/ml doxorubicin for 24 hours, the expressions of mdr1 mRNA, NF-kappa B mRNA and P-gp in K562 cells were increased from 0.171 +/- 0.012, 0.783 +/- 0.090, 7.85 +/- 0.15 to 0.428 +/- 0.012, 1.075 +/- 0.047 and 73.68 +/- 1.84, respectively. Doxorubicin 44-55 nuclear factor kappa B subunit 1 Homo sapiens 100-110 18981184-6 2009 We show that SMAR1 induction by doxorubicin or overexpression produces functional NF-kappaB complexes that are competent for binding to NF-kappaB consensus sequence. Doxorubicin 32-43 nuclear factor kappa B subunit 1 Homo sapiens 82-91 18981184-6 2009 We show that SMAR1 induction by doxorubicin or overexpression produces functional NF-kappaB complexes that are competent for binding to NF-kappaB consensus sequence. Doxorubicin 32-43 nuclear factor kappa B subunit 1 Homo sapiens 136-145 18083229-5 2008 Further, we demonstrate that the sole incubation of MM cells with melphalan or doxorubicin leads to a vast activation of NFkappaB activity. Doxorubicin 79-90 nuclear factor kappa B subunit 1 Homo sapiens 121-129 18083229-6 2008 Additionally, we show that the co-incubation of bortezomib with melphalan or doxorubicin reduces activation of NFkappaB. Doxorubicin 77-88 nuclear factor kappa B subunit 1 Homo sapiens 111-119 18083229-7 2008 These data suggest that the drug-sensitizing effect of bortezomib on MM cells is due to inhibition of melphalan- and doxorubicin-induced activation of NFkappaB activity. Doxorubicin 117-128 nuclear factor kappa B subunit 1 Homo sapiens 151-159 18644995-0 2008 Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Doxorubicin 111-122 nuclear factor kappa B subunit 1 Homo sapiens 61-82 18644995-2 2008 The mechanism of NF-kappaB-mediated chemoresistance remains unclear, with a previous report suggesting that doxorubicin induces this response independent of the inhibitory kappaB kinases (IKK). Doxorubicin 108-119 nuclear factor kappa B subunit 1 Homo sapiens 17-26 18644995-5 2008 The absence of either IKKalpha or IKKbeta or both kinases resulted in impaired induction of NF-kappaB DNA-binding activity in response to doxorubicin. Doxorubicin 138-149 nuclear factor kappa B subunit 1 Homo sapiens 92-101 18644995-7 2008 Knockdown of IKKalpha severely impaired the ability of doxorubicin to initiate NF-kappaB DNA-binding activity. Doxorubicin 55-66 nuclear factor kappa B subunit 1 Homo sapiens 79-88 18644995-9 2008 The inhibition of doxorubicin-induced NF-kappaB activation by the knockdown of either catalytic subunit resulted in increased cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase and increased apoptosis when compared with doxorubicin alone. Doxorubicin 18-29 nuclear factor kappa B subunit 1 Homo sapiens 38-47 18644995-9 2008 The inhibition of doxorubicin-induced NF-kappaB activation by the knockdown of either catalytic subunit resulted in increased cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase and increased apoptosis when compared with doxorubicin alone. Doxorubicin 227-238 nuclear factor kappa B subunit 1 Homo sapiens 38-47 18644995-11 2008 Moreover, we show that IKKalpha plays a critical role in NF-kappaB-mediated chemoresistance in response to doxorubicin and may serve as a potential target in combinational strategies to improve chemotherapeutic response. Doxorubicin 107-118 nuclear factor kappa B subunit 1 Homo sapiens 57-66 17943530-5 2008 Recently we showed that the GnRH agonist triptorelin induces activation of nuclear factor-kappaB (NFkappaB) and thus reduces the apoptosis induced by the cytotoxic agent doxorubicin in human endometrial and ovarian cancer cells. Doxorubicin 170-181 nuclear factor kappa B subunit 1 Homo sapiens 75-96 18400355-0 2008 Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. Doxorubicin 17-28 nuclear factor kappa B subunit 1 Homo sapiens 70-79 18666436-4 2008 The aim of this study was to assess the effects of doxorubicin (DOX) and its analogs (annamycin, WP903) on the NFkappaB activity in human melanoma cells: a sensitive (ME18) and a resistant to DOX (ME18/R) and its possible correlation with cell sensitivity to these drugs. Doxorubicin 51-62 nuclear factor kappa B subunit 1 Homo sapiens 111-119 18666436-4 2008 The aim of this study was to assess the effects of doxorubicin (DOX) and its analogs (annamycin, WP903) on the NFkappaB activity in human melanoma cells: a sensitive (ME18) and a resistant to DOX (ME18/R) and its possible correlation with cell sensitivity to these drugs. Doxorubicin 64-67 nuclear factor kappa B subunit 1 Homo sapiens 111-119 18666436-6 2008 As was shown, DOX, 1.7; 8.6 microM, strongly induced NFkappaB in ME18 cells. Doxorubicin 14-17 nuclear factor kappa B subunit 1 Homo sapiens 53-61 17935137-7 2008 In addition, pretreatment of wortmannin blocked etoposide and doxorubicin induced IkappaB-alpha degradation, NFkappaB activation, phosphorylation of Akt, MDM-2 and forkhead transcription factors. Doxorubicin 62-73 nuclear factor kappa B subunit 1 Homo sapiens 109-117 18028419-10 2008 Finally, western blotting experiments revealed that incubation of myeloma cells with cytotoxic drugs like melphalan or doxorubicin leads to increased phosphorylation and therefore degradation of inhibitor of nuclear factor kappa B (IkappaB) and release of nuclear factor kappa B (NFkappaB). Doxorubicin 119-130 nuclear factor kappa B subunit 1 Homo sapiens 208-230 18028419-10 2008 Finally, western blotting experiments revealed that incubation of myeloma cells with cytotoxic drugs like melphalan or doxorubicin leads to increased phosphorylation and therefore degradation of inhibitor of nuclear factor kappa B (IkappaB) and release of nuclear factor kappa B (NFkappaB). Doxorubicin 119-130 nuclear factor kappa B subunit 1 Homo sapiens 256-278 18028419-10 2008 Finally, western blotting experiments revealed that incubation of myeloma cells with cytotoxic drugs like melphalan or doxorubicin leads to increased phosphorylation and therefore degradation of inhibitor of nuclear factor kappa B (IkappaB) and release of nuclear factor kappa B (NFkappaB). Doxorubicin 119-130 nuclear factor kappa B subunit 1 Homo sapiens 280-288 17943530-5 2008 Recently we showed that the GnRH agonist triptorelin induces activation of nuclear factor-kappaB (NFkappaB) and thus reduces the apoptosis induced by the cytotoxic agent doxorubicin in human endometrial and ovarian cancer cells. Doxorubicin 170-181 nuclear factor kappa B subunit 1 Homo sapiens 98-106 17943530-6 2008 The triptorelin-induced reduction of doxorubicin-induced apoptosis was blocked by inhibition of NFkappaB translocation into the nucleus. Doxorubicin 37-48 nuclear factor kappa B subunit 1 Homo sapiens 96-104 17704247-5 2007 Electrophoretic mobility-shift assay (EMSA) was performed to evaluate nuclear factor-kappaB (NF-kappaB) binding activity induced by doxorubicin. Doxorubicin 132-143 nuclear factor kappa B subunit 1 Homo sapiens 70-91 17912235-0 2008 RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Doxorubicin 98-109 nuclear factor kappa B subunit 1 Homo sapiens 35-45 17912235-3 2008 By achieving selective, targeted, and early inhibition of NF-kappaB activity, we demonstrate that NF-kappaB plays a critical role in Dox-induced chemoresistance by regulating genes involved in proliferation (Ki-67), response to DNA damage (GADD153), antiapoptosis (Bcl-XL), and pH regulation (CA9). Doxorubicin 133-136 nuclear factor kappa B subunit 1 Homo sapiens 58-67 17912235-3 2008 By achieving selective, targeted, and early inhibition of NF-kappaB activity, we demonstrate that NF-kappaB plays a critical role in Dox-induced chemoresistance by regulating genes involved in proliferation (Ki-67), response to DNA damage (GADD153), antiapoptosis (Bcl-XL), and pH regulation (CA9). Doxorubicin 133-136 nuclear factor kappa B subunit 1 Homo sapiens 98-107 17912235-4 2008 This Dox-induced NF-kappaB activation and subsequent chemoresistance is dependent on expression of p53. Doxorubicin 5-8 nuclear factor kappa B subunit 1 Homo sapiens 17-26 17912235-5 2008 We also demonstrate that NF-kappaB promotes angiogenesis in the presence of Dox via the hypoxia-inducible factor-1alpha/vascular endothelial growth factor (HIF-1alpha/VEGF) pathway, revealing a previously unknown mechanism of NSCLC resistance to Dox. Doxorubicin 76-79 nuclear factor kappa B subunit 1 Homo sapiens 25-34 17912235-5 2008 We also demonstrate that NF-kappaB promotes angiogenesis in the presence of Dox via the hypoxia-inducible factor-1alpha/vascular endothelial growth factor (HIF-1alpha/VEGF) pathway, revealing a previously unknown mechanism of NSCLC resistance to Dox. Doxorubicin 246-249 nuclear factor kappa B subunit 1 Homo sapiens 25-34 17890907-0 2007 Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Doxorubicin 84-95 nuclear factor kappa B subunit 1 Homo sapiens 32-42 17890907-5 2007 Doxorubicin, an anticancer agent used in patients with breast cancer, activated NF kappa B and appeared to be less effective in cells expressing predominantly members of the canonical IKK/NF kappa B. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 80-90 17890907-5 2007 Doxorubicin, an anticancer agent used in patients with breast cancer, activated NF kappa B and appeared to be less effective in cells expressing predominantly members of the canonical IKK/NF kappa B. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 188-198 17890907-6 2007 Two NF kappa B inhibitors, bortezomib and NEMO-Binding Domain Inhibitory Peptide, prevented doxorubicin-induced NF kappa B activation and increased doxorubicin antitumor effects in BT-474 cells. Doxorubicin 92-103 nuclear factor kappa B subunit 1 Homo sapiens 4-14 17890907-6 2007 Two NF kappa B inhibitors, bortezomib and NEMO-Binding Domain Inhibitory Peptide, prevented doxorubicin-induced NF kappa B activation and increased doxorubicin antitumor effects in BT-474 cells. Doxorubicin 92-103 nuclear factor kappa B subunit 1 Homo sapiens 112-122 17890907-6 2007 Two NF kappa B inhibitors, bortezomib and NEMO-Binding Domain Inhibitory Peptide, prevented doxorubicin-induced NF kappa B activation and increased doxorubicin antitumor effects in BT-474 cells. Doxorubicin 148-159 nuclear factor kappa B subunit 1 Homo sapiens 4-14 17890907-9 2007 To conclude, NF kappa B inhibition sensitized cells to doxorubicin, implying directly p65, p52, c-Rel and IKKgamma/NEMO subunits in chemoresistance, but not RelB. Doxorubicin 55-66 nuclear factor kappa B subunit 1 Homo sapiens 13-23 17890907-10 2007 These findings suggest that selective inhibition of the canonical NF kappa B pathway is sufficient to improve doxorubicin antitumor effects. Doxorubicin 110-121 nuclear factor kappa B subunit 1 Homo sapiens 66-76 17873517-6 2007 In addition, indomethacin decreased the expression of NFkappaB-regulated gene products involved in rhLTalpha-induced anti-apoptosis (XIAP, cFLIP and cIAP-1), which may explain its sensitization of tumor cells to rhLTalpha and/or cisplatin/adriamycin. Doxorubicin 239-249 nuclear factor kappa B subunit 1 Homo sapiens 54-62 17704247-5 2007 Electrophoretic mobility-shift assay (EMSA) was performed to evaluate nuclear factor-kappaB (NF-kappaB) binding activity induced by doxorubicin. Doxorubicin 132-143 nuclear factor kappa B subunit 1 Homo sapiens 93-102 17704247-11 2007 In addition, NF-kappaB, activated by doxorubicin, induced transgene transcription under the control of the CMV promoter, which possesses an NF-kappaB binding site. Doxorubicin 37-48 nuclear factor kappa B subunit 1 Homo sapiens 13-22 17704247-11 2007 In addition, NF-kappaB, activated by doxorubicin, induced transgene transcription under the control of the CMV promoter, which possesses an NF-kappaB binding site. Doxorubicin 37-48 nuclear factor kappa B subunit 1 Homo sapiens 140-149 17638900-7 2007 Temozolomide also inhibits NF-kappaB activated by inducers other than TNFalpha, including lipopolysaccharide, doxorubicin, and phorbol 12-myristate 13-acetate. Doxorubicin 110-121 nuclear factor kappa B subunit 1 Homo sapiens 27-36 17218010-0 2007 Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines. Doxorubicin 92-103 nuclear factor kappa B subunit 1 Homo sapiens 11-20 17097285-0 2007 Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Doxorubicin 19-30 nuclear factor kappa B subunit 1 Homo sapiens 74-83 17440102-7 2007 Nuclear factor-kappaB (NF-kappaB) signaling activity is associated with AXL expression and may play an important role in the enhancement of invasiveness and doxorubicin resistance, as shown by using the NF-kappaB inhibitor, sulfasalazine, and IkappaB dominant-negative transfectants. Doxorubicin 157-168 nuclear factor kappa B subunit 1 Homo sapiens 0-21 17440102-7 2007 Nuclear factor-kappaB (NF-kappaB) signaling activity is associated with AXL expression and may play an important role in the enhancement of invasiveness and doxorubicin resistance, as shown by using the NF-kappaB inhibitor, sulfasalazine, and IkappaB dominant-negative transfectants. Doxorubicin 157-168 nuclear factor kappa B subunit 1 Homo sapiens 23-32 17097285-0 2007 Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Doxorubicin 119-130 nuclear factor kappa B subunit 1 Homo sapiens 74-83 17097285-9 2007 We found that celecoxib and PSC833, but not indomethacin or NS398, almost completely inhibited basal- and dox induced NF-kappaB gene-reporter activity and p65 subunit nuclear translocation. Doxorubicin 106-109 nuclear factor kappa B subunit 1 Homo sapiens 118-127 17097285-10 2007 Furthermore, the NF-kappaB inhibitor PDTC mimicked the actions of celecoxib and PSC833 on cell growth and on intracellular accumulation of dox, suggesting that NF-kappaB is functionally involved in the actions of these compounds. Doxorubicin 139-142 nuclear factor kappa B subunit 1 Homo sapiens 17-26 17097285-10 2007 Furthermore, the NF-kappaB inhibitor PDTC mimicked the actions of celecoxib and PSC833 on cell growth and on intracellular accumulation of dox, suggesting that NF-kappaB is functionally involved in the actions of these compounds. Doxorubicin 139-142 nuclear factor kappa B subunit 1 Homo sapiens 160-169 15878982-7 2005 Rapamycin inhibited doxorubicin-induced NF-kappaB in ALL samples. Doxorubicin 20-31 nuclear factor kappa B subunit 1 Homo sapiens 40-49 17215959-2 2006 Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 56-62 17215959-2 2006 Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 64-73 17132229-2 2006 Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 56-62 17132229-2 2006 Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 64-73 16479163-8 2006 It was also shown that the association of p21 with p50 and other components of the pol delta complex increased in MCF7 cells treated with adriamycin. Doxorubicin 138-148 nuclear factor kappa B subunit 1 Homo sapiens 51-54 16479163-9 2006 Our results suggested that p50 might target or anchor p21 to pol delta complex upon certain DNA damage such as adriamycin treatment. Doxorubicin 111-121 nuclear factor kappa B subunit 1 Homo sapiens 27-30 16322301-0 2005 The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Doxorubicin 102-113 nuclear factor kappa B subunit 1 Homo sapiens 33-39 16322301-11 2005 CONCLUSION: We conclude that nuclear localization of NF-kappaB correlates with bcl-2 and bax expression and that the NF-kappaB/bcl-2 pathway may be associated with a poor response to neoadjuvant doxorubicin-based chemotherapy. Doxorubicin 195-206 nuclear factor kappa B subunit 1 Homo sapiens 53-62 16322301-11 2005 CONCLUSION: We conclude that nuclear localization of NF-kappaB correlates with bcl-2 and bax expression and that the NF-kappaB/bcl-2 pathway may be associated with a poor response to neoadjuvant doxorubicin-based chemotherapy. Doxorubicin 195-206 nuclear factor kappa B subunit 1 Homo sapiens 117-126 15899819-0 2005 Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Doxorubicin 33-44 nuclear factor kappa B subunit 1 Homo sapiens 0-21 15905586-4 2005 We found that ACA suppressed NF-kappaB activation induced by a wide variety of inflammatory and carcinogenic agents, including TNF, IL-1beta, PMA, LPS, H(2)O(2), doxorubicin, and cigarette smoke condensate. Doxorubicin 162-173 nuclear factor kappa B subunit 1 Homo sapiens 29-38 15899819-7 2005 Together these data show that NF-kappaB signaling induced by doxorubicin reduces expression of NF-kappaB-dependent genes in cancer cells. Doxorubicin 61-72 nuclear factor kappa B subunit 1 Homo sapiens 30-39 15899819-0 2005 Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Doxorubicin 33-44 nuclear factor kappa B subunit 1 Homo sapiens 107-128 15899819-7 2005 Together these data show that NF-kappaB signaling induced by doxorubicin reduces expression of NF-kappaB-dependent genes in cancer cells. Doxorubicin 61-72 nuclear factor kappa B subunit 1 Homo sapiens 95-104 15899819-3 2005 We have assessed the effect of doxorubicin, an anthracycline in widespread clinical use, on NF-kappaB activation and expression of antiapoptotic genes in breast cancer cells. Doxorubicin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 92-101 15899819-4 2005 We show that doxorubicin treatment activates NF-kappaB signaling and produces NF-kappaB complexes that are competent for NF-kappaB binding in vitro. Doxorubicin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 45-54 15899819-4 2005 We show that doxorubicin treatment activates NF-kappaB signaling and produces NF-kappaB complexes that are competent for NF-kappaB binding in vitro. Doxorubicin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 78-87 15899819-4 2005 We show that doxorubicin treatment activates NF-kappaB signaling and produces NF-kappaB complexes that are competent for NF-kappaB binding in vitro. Doxorubicin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 78-87 15899819-6 2005 We show that doxorubicin treatment produces RelA, which is deficient in phosphorylation and acetylation and which blocks NF-kappaB signaling in a histone deacetylase-independent manner, and we show that NF-kappaB activated by doxorubicin does not remain stably bound to kappaB elements in vivo. Doxorubicin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 121-130 15899819-6 2005 We show that doxorubicin treatment produces RelA, which is deficient in phosphorylation and acetylation and which blocks NF-kappaB signaling in a histone deacetylase-independent manner, and we show that NF-kappaB activated by doxorubicin does not remain stably bound to kappaB elements in vivo. Doxorubicin 13-24 nuclear factor kappa B subunit 1 Homo sapiens 203-212 15899819-6 2005 We show that doxorubicin treatment produces RelA, which is deficient in phosphorylation and acetylation and which blocks NF-kappaB signaling in a histone deacetylase-independent manner, and we show that NF-kappaB activated by doxorubicin does not remain stably bound to kappaB elements in vivo. Doxorubicin 226-237 nuclear factor kappa B subunit 1 Homo sapiens 203-212 15571967-0 2004 Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Doxorubicin 19-30 nuclear factor kappa B subunit 1 Homo sapiens 39-48 15810080-0 2005 Hepatic preconditioning of doxorubicin in stop-flow chemotherapy: NF-kappaB/IkappaB-alpha pathway and expression of HSP72. Doxorubicin 27-38 nuclear factor kappa B subunit 1 Homo sapiens 66-75 15810080-13 2005 CONCLUSION: Doxorubicin renders the liver to be tolerant to the hepatic influence in SFC in a porcine model through the NF-kappaB/IkappaB-alpha pathway with the expression of HSP72. Doxorubicin 12-23 nuclear factor kappa B subunit 1 Homo sapiens 120-129 15681168-4 2005 If cells were treated with antineoplastic agents (taxol, doxorubicin or vinblastine), nuclear translocation of two NF-kappaB proteins (p50 and p65) was >25% greater in biotin-deficient compared with biotin-supplemented cells. Doxorubicin 57-68 nuclear factor kappa B subunit 1 Homo sapiens 115-124 15681168-4 2005 If cells were treated with antineoplastic agents (taxol, doxorubicin or vinblastine), nuclear translocation of two NF-kappaB proteins (p50 and p65) was >25% greater in biotin-deficient compared with biotin-supplemented cells. Doxorubicin 57-68 nuclear factor kappa B subunit 1 Homo sapiens 135-138 15571967-3 2004 Doxorubicin is a striking NF-kappaB/Rel-inducer, we therefore investigated if rapamycin interfered with the pathway of NF-kappaB/Rel activation, i.e. IkappaBalpha-phosphorylation, -degradation and NF-kappaB/Rel nuclear translocation, and found that the macrolide agent caused a block of IKK kinase activity that was responsible for a reduced nuclear translocation of transcription factors. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 26-35 15571967-4 2004 Western blots for Bcl-2 and c-IAP1 showed increased levels of these anti-apoptotic proteins in cells incubated with doxorubicin, in accordance with NF-kappaB/Rel activation, while rapamycin clearly downmodulated these proteins, in line with its pro-apoptotic ability. Doxorubicin 116-127 nuclear factor kappa B subunit 1 Homo sapiens 148-157 15302589-7 2004 In contrast, we observed that overexpression of Max resulted in a marked increase in basal promoter activity and synergistically enhanced phorbolester- and doxorubicin-induced NFkappaB-mediated Fas ligand promoter activity. Doxorubicin 156-167 nuclear factor kappa B subunit 1 Homo sapiens 176-184 15102937-0 2004 Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Doxorubicin 63-74 nuclear factor kappa B subunit 1 Homo sapiens 15-21 12871783-4 2003 In this study, we transferred the "super-repressor" form of the NF-kappaB inhibitor by adenoviral vector (ad-IkappaBalpha) to human lung cancer cell lines with resistant to cisplatin (PC-14-DDP) and adriamycin (PC-14-ADR), and observed the sensitivity change. Doxorubicin 199-209 nuclear factor kappa B subunit 1 Homo sapiens 64-73 15053878-2 2004 Here, we demonstrate that NF-kappa B induced by cytotoxic stimuli, such as ultraviolet light (UV-C) and the chemotherapeutic drugs daunorubicin/doxorubicin, is functionally distinct to that seen with the inflammatory cytokine TNF and is an active repressor of antiapoptotic gene expression. Doxorubicin 144-155 nuclear factor kappa B subunit 1 Homo sapiens 26-36 12871783-8 2003 These data demonstrated that ad-IkappaBalpha blockade of chemotherapeutic induced NF-kappaB activation increased apoptosis induction and the chemosensitivity of lung cancer cell lines with acquired resistance to cisplatin and adriamycin. Doxorubicin 226-236 nuclear factor kappa B subunit 1 Homo sapiens 82-91 15102937-11 2004 In summary, our data clearly indicate that doxorubicin induces cathepsin B expression and activity via NF-kappaB. Doxorubicin 43-54 nuclear factor kappa B subunit 1 Homo sapiens 103-112 12871783-5 2003 Electrophoretic mobility shift assay showed that ad-IkappaBalpha blocked the activation of NF-kappaB induced by cisplatin and adriamycin. Doxorubicin 126-136 nuclear factor kappa B subunit 1 Homo sapiens 91-100 12818362-9 2003 Suppression of NF-kappa B activation by transfection of a dominant negative I kappa B alpha prevented the development of drug resistance, indicating that the upregulated NF-kappa B activity was positively correlated with the low-dose doxorubicin-induced drug resistance. Doxorubicin 234-245 nuclear factor kappa B subunit 1 Homo sapiens 15-25 12818362-9 2003 Suppression of NF-kappa B activation by transfection of a dominant negative I kappa B alpha prevented the development of drug resistance, indicating that the upregulated NF-kappa B activity was positively correlated with the low-dose doxorubicin-induced drug resistance. Doxorubicin 234-245 nuclear factor kappa B subunit 1 Homo sapiens 170-180 11996883-3 2002 Both cisplatin and doxorubicin activated nuclear ERK2 and nuclear transcription factor kappa B (NF kappa B) of SiHa cells. Doxorubicin 19-30 nuclear factor kappa B subunit 1 Homo sapiens 96-106 12517772-6 2003 Using this animal model, we report that NF-kappaB is activated in response to doxorubicin-induced genotoxic stress and exerts a pronounced protective effect in opposing chemotherapy-induced tissue damage. Doxorubicin 78-89 nuclear factor kappa B subunit 1 Homo sapiens 40-49 12875694-11 2003 NF-kappaB in untransfected cells was activated by Doxorubicin in a dose-dependent manner, but that in SMMC7721-MT cells was not induced at low concentrations of Doxorubicin. Doxorubicin 50-61 nuclear factor kappa B subunit 1 Homo sapiens 0-9 12654725-5 2003 In wild-type fibroblasts, DNA damage induced by agents such as adriamycin, campthothecin, and ionizing radiation induces NF-kappaB activation. Doxorubicin 63-73 nuclear factor kappa B subunit 1 Homo sapiens 121-130 12007574-2 2002 We systematically examined the baseline levels of NF-kappaB activity of representative carcinoma cell lines, and the change of NF-kappaB activity in response to a challenge with four major anticancer drugs (doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel). Doxorubicin 207-218 nuclear factor kappa B subunit 1 Homo sapiens 127-136 12007574-7 2002 In particular, when cells were pretreated with common biologic modulators such as tamoxifen, dexamethasone, and curcumin, the doxorubicin-induced NF-kappaB activation was attenuated significantly. Doxorubicin 126-137 nuclear factor kappa B subunit 1 Homo sapiens 146-155 11996883-5 2002 The activation of NF kappa B by cisplatin or doxorubicin was not due to the degradation of cytoplasmic I kappa B alpha, as demonstrated by western blotting. Doxorubicin 45-56 nuclear factor kappa B subunit 1 Homo sapiens 18-28 11679590-0 2001 NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. Doxorubicin 31-42 nuclear factor kappa B subunit 1 Homo sapiens 0-10 11803469-2 2002 We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Doxorubicin 70-81 nuclear factor kappa B subunit 1 Homo sapiens 93-102 11679590-8 2001 Doxorubicin induced NF-kappa B transcriptional activation in association with I-kappa B alpha degradation prior to loss of cell viability. Doxorubicin 0-11 nuclear factor kappa B subunit 1 Homo sapiens 20-30 11679590-9 2001 Surprisingly, the antioxidant and NF-kappa B inhibitor pyrrolidine dithiocarbamate blocked doxorubicin-induced NF-kappa B transcriptional activation and provided profound protection against doxorubicin killing. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 34-44 11679590-9 2001 Surprisingly, the antioxidant and NF-kappa B inhibitor pyrrolidine dithiocarbamate blocked doxorubicin-induced NF-kappa B transcriptional activation and provided profound protection against doxorubicin killing. Doxorubicin 91-102 nuclear factor kappa B subunit 1 Homo sapiens 111-121 11679590-9 2001 Surprisingly, the antioxidant and NF-kappa B inhibitor pyrrolidine dithiocarbamate blocked doxorubicin-induced NF-kappa B transcriptional activation and provided profound protection against doxorubicin killing. Doxorubicin 190-201 nuclear factor kappa B subunit 1 Homo sapiens 34-44 11679590-11 2001 Together these findings show that NF-kappa B activation mediates doxorubicin-induced cell death without evidence of caspase function and suggest that cisplatin and doxorubicin engage different death pathways to kill neuroblastoma cells. Doxorubicin 65-76 nuclear factor kappa B subunit 1 Homo sapiens 34-44 11679590-11 2001 Together these findings show that NF-kappa B activation mediates doxorubicin-induced cell death without evidence of caspase function and suggest that cisplatin and doxorubicin engage different death pathways to kill neuroblastoma cells. Doxorubicin 164-175 nuclear factor kappa B subunit 1 Homo sapiens 34-44 10979973-8 2000 Attenuation of NFkappaB activity by ectopic expression of transdominant repressor of IkappaB sensitized HL-60/Bcr-Abl and K562 cells to TNF-alpha but not to apoptosis induced by Ara-C or doxorubicin. Doxorubicin 187-198 nuclear factor kappa B subunit 1 Homo sapiens 15-23 11314019-0 2001 Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Doxorubicin 112-123 nuclear factor kappa B subunit 1 Homo sapiens 14-23 11314019-4 2001 Treatment with various NF-kappaB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the IkappaBalpha super-repressor, strongly enhanced the apoptotic effects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Doxorubicin 188-199 nuclear factor kappa B subunit 1 Homo sapiens 23-32 11061544-13 2000 Triptorelin-induced reduction of Doxorubicin-induced apoptosis was blocked by SN50-mediated inhibition of NFkappaB translocation into the nucleus. Doxorubicin 33-44 nuclear factor kappa B subunit 1 Homo sapiens 106-114 11061544-14 2000 We conclude that LHRH induces activation of NFkappaB and thus reduces Doxorubicin-induced apoptosis in human ovarian cancer cells. Doxorubicin 70-81 nuclear factor kappa B subunit 1 Homo sapiens 44-52 11262181-6 2001 Specific blockage of Rho signaling by Clostridium difficile toxin B attenuated UV- and doxorubicin-induced activation of NF-kappaB, but did not affect stimulation of NF-kappaB by TNFalpha. Doxorubicin 87-98 nuclear factor kappa B subunit 1 Homo sapiens 121-130 11059688-4 2000 We demonstrate that both TNFalpha and adriamycin activate NFkappaB in hepatoma cells. Doxorubicin 38-48 nuclear factor kappa B subunit 1 Homo sapiens 58-66